X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs STERLING BIOTECH - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS STERLING BIOTECH IPCA LABS/
STERLING BIOTECH
 
P/E (TTM) x 44.4 -1.6 - View Chart
P/BV x 3.4 0.1 5,366.8% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 IPCA LABS   STERLING BIOTECH
EQUITY SHARE DATA
    IPCA LABS
Mar-17
STERLING BIOTECH
Dec-13
IPCA LABS/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs64311 6,123.8%   
Low Rs5033 14,788.2%   
Sales per share (Unadj.) Rs254.426.8 949.1%  
Earnings per share (Unadj.) Rs16.1-15.0 -107.4%  
Cash flow per share (Unadj.) Rs29.8-5.5 -545.0%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.654.9 354.5%  
Shares outstanding (eoy) m126.20267.87 47.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.30.3 868.6%   
Avg P/E ratio x35.7-0.5 -7,672.3%  
P/CF ratio (eoy) x19.2-1.3 -1,512.4%  
Price / Book Value ratio x2.90.1 2,325.3%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,3001,862 3,883.6%   
No. of employees `00013.31.4 982.5%   
Total wages/salary Rs m6,960547 1,272.8%   
Avg. sales/employee Rs Th2,413.55,303.3 45.5%   
Avg. wages/employee Rs Th523.2403.8 129.5%   
Avg. net profit/employee Rs Th152.4-2,959.0 -5.2%   
INCOME DATA
Net Sales Rs m32,1067,181 447.1%  
Other income Rs m22643 529.8%   
Total revenues Rs m32,3327,223 447.6%   
Gross profit Rs m4,448947 469.7%  
Depreciation Rs m1,7302,543 68.0%   
Interest Rs m2414,377 5.5%   
Profit before tax Rs m2,703-5,931 -45.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m675-1,924 -35.1%   
Profit after tax Rs m2,028-4,007 -50.6%  
Gross profit margin %13.913.2 105.1%  
Effective tax rate %25.032.4 77.0%   
Net profit margin %6.3-55.8 -11.3%  
BALANCE SHEET DATA
Current assets Rs m17,34014,335 121.0%   
Current liabilities Rs m9,55949,809 19.2%   
Net working cap to sales %24.2-494.0 -4.9%  
Current ratio x1.80.3 630.3%  
Inventory Days Days100403 24.9%  
Debtors Days Days57171 33.3%  
Net fixed assets Rs m20,77955,432 37.5%   
Share capital Rs m252268 94.2%   
"Free" reserves Rs m24,49913,935 175.8%   
Net worth Rs m24,55314,701 167.0%   
Long term debt Rs m3,5179,478 37.1%   
Total assets Rs m39,59573,988 53.5%  
Interest coverage x12.2-0.4 -3,444.3%   
Debt to equity ratio x0.10.6 22.2%  
Sales to assets ratio x0.80.1 835.5%   
Return on assets %5.70.5 1,144.0%  
Return on equity %8.3-27.3 -30.3%  
Return on capital %10.5-6.4 -163.2%  
Exports to sales %48.625.9 187.8%   
Imports to sales %14.20.2 8,379.7%   
Exports (fob) Rs m15,6171,860 839.7%   
Imports (cif) Rs m4,57112 37,467.2%   
Fx inflow Rs m15,6171,860 839.7%   
Fx outflow Rs m5,82825 23,413.8%   
Net fx Rs m9,7901,835 533.5%   
CASH FLOW
From Operations Rs m2,7641,719 160.8%  
From Investments Rs m-1,432-3,148 45.5%  
From Financial Activity Rs m-1,5911,426 -111.6%  
Net Cashflow Rs m-259-3 7,611.8%  

Share Holding

Indian Promoters % 45.9 33.9 135.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.0 -  
FIIs % 25.3 9.9 255.6%  
ADR/GDR % 0.0 16.9 -  
Free float % 17.4 39.3 44.3%  
Shareholders   36,892 21,482 171.7%  
Pledged promoter(s) holding % 2.1 55.9 3.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   ORCHID PHARMA LTD  WYETH LTD  ASTRAZENECA PHARMA  SUVEN LIFE  CIPLA  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 22, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS